title: [JAK2 inhibitors].
abstract: Pharmacological inhibition of the kinase activity of JAK proteins can interfere with the signaling of immunomodulatory cytokines and block the constitutive activation of the JAK-STAT pathway that characterizes certain malignancies, including chronic myeloproliferative neoplasms. JAK inhibitors may, therefore, be useful to treat malignancies as well as inflammatory or immune disorders. Currently, the most significant advances have been made in the treatment of myelofibrosis, where these drugs may lead to a remarkable improvement in the control of hyperproliferative manifestations. However, available data suggest that this treatment is not curative of myelofibrosis. In general, JAK2 inhibition induces cytopaenias, with this being considered a class side-effect. By contrast, the extrahaematologic toxicity profile varies significantly among the different JAK inhibitors. At present, there are several clinical trials evaluating the combination of ruxolitinib with other drugs, in order to improve its therapeutic activity as well as reducing haematologic toxicity.
authors.affiliation: Servicio de Hematología, Hospital Clínico Universitario, Valencia, España. Electronic address: hernandez_jca@gva.es.
authors.forename: Juan Carlos
authors.initials: JC
authors.lastname: Hernández Boluda
authors.affiliation: Servicio de Hematología, Hospital Clínico Universitario, Valencia, España.
authors.forename: Montse
authors.initials: M
authors.lastname: Gómez
authors.affiliation: Servicio de Hematología, Hospital Clínico Universitario, Valencia, España.
authors.forename: Ariadna
authors.initials: A
authors.lastname: Pérez
mesh_terms: D001327:Autoimmune Diseases / Q000188:drug therapy / Q000201:enzymology; D006801:Humans; D053614:Janus Kinase 2 / Q000037:antagonists & inhibitors*; D009570:Nitriles; D011087:Polycythemia Vera / Q000188:drug therapy* / Q000201:enzymology; D055728:Primary Myelofibrosis / Q000188:drug therapy* / Q000201:enzymology; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011720:Pyrazoles / Q000627:therapeutic use; D011743:Pyrimidines; D013920:Thrombocythemia, Essential / Q000188:drug therapy* / Q000201:enzymology; D016896:Treatment Outcome
chemical_list: D009570:Nitriles; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011743:Pyrimidines; C540383:ruxolitinib; C507924:JAK2 protein, human; D053614:Janus Kinase 2
keywords: Enfermedades autoinmunitarias; Immune disorders; Inhibidores de JAK2; JAK2 inhibitors; Mielofibrosis; Myelofibrosis; Ruxolitinib; Toxicidad; Toxicity